Rhythm Pharmaceuticals, Inc. (RYTM)
$111.44+1.31%Close
BUYBEAR · day 3
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $7.6B
- Avg volume
- 761.9K
- Beta
- 1.97
- P/E (TTM)
- -35.83
- Short % float
- 16.96%
- Days to cover
- 16.2
- SI change
- -1.4%
- 1W
- -3.47%
- 1M
- +9.15%
- 3M
- +26.87%
- YTD
- +6.12%
- vs SPY 1W
- -2.27%
- vs SPY 1M
- +5.83%
- vs SPY 3M
- +24.48%
- vs SPY YTD
- -5.63%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- SEPNBUYSepterna, Inc.CRISISQ 29$40.52+1.30%
- ATECBUYAlphatec Holdings, Inc.RECOVERYQ -1$9.24-2.53%
- HKPDSELLCellyan Biotechnology Co., LtdCRISISQ -24$0.37-9.76%
- MYGNSELLMyriad Genetics, Inc.CRISISQ 5$3.05-4.69%
- EXOZBUYeXoZymes, Inc.RECOVERYQ 0$6.95-2.80%
- MASSBUY908 Devices Inc.BULLQ 1$10.92+2.25%
- OMSELLOutset Medical, Inc.CRISISQ -34$4.19-0.48%
- UEECSELLUnited Health Products, Inc.CRISISQ 8$0.04+0.00%
- BBLGSELLBone Biologics CorporationCRISISQ -23$0.61-3.17%
- SNOABUYSonoma Pharmaceuticals, Inc.RECOVERYQ -9$1.34+0.00%
- AGLSELLAgilon Health, Inc.RECOVERYQ -4$93.79-2.89%
- MGXSELLMetagenomi, Inc. Common StockRECOVERYQ -19$1.21-1.63%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDBUYRevolution Medicines, Inc.$44.5BBULLQ 31$209.46+1.01%
- PTGXBUYProtagonist Therapeutics, Inc.$9.9BBULLQ 33$154.32+0.26%
- NUVLBUYNuvalent, Inc.$9.1BBULLQ 42$123.96+0.00%
- ACLXArcellx, Inc.$6.7B$115.07
- KNSABUYKiniksa Pharmaceuticals International, plc$6.0BBULLQ 23$79.03+0.44%
- AKROAkero Therapeutics, Inc.$4.5B$54.65
- RLAYBUYRelay Therapeutics, Inc.$4.3BBULLQ 4$19.44+1.65%
- QUREBUYuniQure N.V.$3.4BRECOVERYQ 20$48.37-1.88%
- VRDNBUYViridian Therapeutics, Inc.$2.8BRECOVERYQ -2$24.29-1.11%
- STOKBUYStoke Therapeutics, Inc.$2.1BRECOVERYQ 13$32.29+0.09%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.7BRECOVERYQ 18$19.65-0.41%
- CGEMBUYCullinan Therapeutics, Inc.$1.3BBULLQ 6$21.68+0.65%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 7
- GROWTH
- 19
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-48.3%
REV YoY-
ROE-80.5%
EPS YoY-
ROA-47.0%
GROSS89
OP-84
NET-86
[VALUATION]
P/E TTM-35.83
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B35.18
P/FCF-
EV/EBITDA-41.05
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.69
ALTMAN Z-
CURR RATIO3.45
ND/EBITDA-
BETA1.97
